



ATTORNEY'S DOCKET NO.: R0547/7007(ERG/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: LIAO, James K., et al.  
Serial No.: 09/273,445  
Filed: March 19, 1999  
For: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE  
BY HMG-COA REDUCTASE INHIBITORS  
Examiner: Webman E. J.  
Art Unit: 1617

TECH CENTER 1600/2900

AUG 10 2001

RECEIVED

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 10th day of August, 2001.

Konstantinos Andrikopoulos  
Konstantinos Andrikopoulos

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

TRANSMITTAL

Sir:

Transmitted herewith are the following:

- ☒ Response to Restriction Requirement and Amendment
- ☒ Two Checks amounting to a total of \$445.00 (\$55.00 + \$390.00)(Three Month Extension of Time)
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

Two checks amounting to a total of \$445.00 (\$55.00 + \$390.00) are enclosed herewith to cover the 3 month extension fee required for the filing of the response. If the fee is insufficient, the balance may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

Konstantinos Andrikopoulos  
Konstantinos Andrikopoulos  
Reg. No. P-48,915  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
Telephone: (617) 720-3500

09/273/2001 COMM1 00000040 09273445

01 08-17

445.00 0P

Attorney Docket No. R0547/7007 (ERG/KA)  
Date: August 10, 2001  
xAugust 10, 2001



ATTORNEY'S DOCKET NO.: R0547/7007 (RG/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: LIAO, James K., et al.  
Serial No.: 09/273,445  
Filed: March 19, 1999  
For: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE  
BY HMG-COA REDUCTASE INHIBITORS  
Examiner: Webman E. J.  
Art Unit: 1617

TECH CENTER 1600/2940

AUG 20 2001

RECEIVED

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 10th day of August, 2001.

Konstantinos Andrikopoulos  
Konstantinos Andrikopoulos

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

**RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT**

Sir:

This is in response to the Office Action (Paper No. 11) mailed from the United States Patent and Trademark Office on April 10, 2001. A Petition for a Three-Month Extension of Time and appropriate fee are submitted concurrently herewith.

Please amend the above-identified application as follows:

In the Claims:

Please cancel claims 169-172.

Please amend claim 167 as follows:

167.(Amended) A method for increasing blood flow in a tissue of a nonhypercholesterolemic subject, comprising:  
administering to a nonhypercholesterolemic subject in need of such treatment a HMG-CoA  
reductase inhibitor in an amount effective to increase endothelial cell Nitric Oxide Synthase activity in the tissue of the subject.